UNSPSC 51352205: Hexestrol

This classification denotes a non-steroidal estrogen with the molecular formula C18H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10BI795R7D, chemically known as 4,4-(1,2-diethylethylene)diphenol but generally known as hexestrol, which bears US NIH Compound Identifier 3606. European Medicines Agency schedules Hexestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG. The term HEXESTROL is an International Non-Proprietary Name.

UNSPSC 51352205 Hexestrol, a Commodity code, encompasses pharmaceutical products supplied through cooperative purchasing agreements that state and local governments use to stock medical and healthcare facility inventories. The recent activity under this code reflects broader state and local procurement of generic pharmaceuticals and over-the-counter products managed through multistate cooperative vehicles rather than hexestrol as a single-drug commodity. State procurement offices and health departments, working through cooperative purchasing alliances, solicit manufacturers and authorized wholesalers to supply comprehensive pharmaceutical catalogs to participating agencies across multiple jurisdictions. The scope includes detailed product specifications tied to National Drug Codes, manufacturing compliance (cGMP and Drug Supply Chain Security Act certification), distribution through authorized wholesalers with chargeback systems, and pricing flexibility across flat-rate, net-price, and WAC-minus structures. Insurance requirements (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000) and FDA compliance with minimum shelf-life specifications are standard contract conditions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products serving Minnesota, Oregon, and other participating states. The procurement prioritizes price competitiveness (weighted at 75 percent of evaluation), with secondary emphasis on fixed pricing, administrative compliance, EDI capability, and a 3 percent administrative fee structure. Manufacturers must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and be prepared to supply products by May 15, 2026 for contract effectiveness on July 1, 2026. The two-year contract term carries optional MMCAP extensions and performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.